Proveris partners with Australian universities on new method of characterizing pharmaceutical aerosols

Aerosol characterization specialist Proveris Scientific has announced that it is working with the University of Sydney and Macquarie University to develop a new method of measuring the surface area of pharmaceutical aerosol particles using optical tomography technology. The project is funded by the Australian Research Council Linkage Program and will be led by Hak-Kim Chan and Agisilaos Kourmatzis of the University of Sydney. Shaokoon Cheng of Macquarie University will join them in the research effort.

According to Proveris, which developed the concept for the new method, “The project aims to develop an innovative optical tomography technology capable of direct and real-time measurement of the surface area of airborne particles. By coupling advanced laser diagnostic tools with physiological models and in vitro characterization techniques, the research team will investigate critical relationships between the surface area of an aerosol and its dissolution when delivered to a target. The outcomes will enable aerosol device manufacturers to develop and market more advanced and highly specific products.”

Proveris Scientific founder and CEO Dino Farina commented, “Significantly enhancing comparative in vivo results utilizing predictive in-vitro technologies for inhaled aerosol characterization is a critical need in providing safer and more efficacious drugs to patients worldwide. Having the ability to work with these three top researchers on this new technology is exciting and will result in technology that will advance inhalation science and help make it a more effective route for drug delivery.”

Hak-Kim Chan said, “We are really thrilled to have this excellent opportunity  conducting joint R&D with Proveris in developing a novel technology platform that can shift the paradigm in the field. This project marks the beginning of a long-term relationship with Proveris to maximize mutual beneficial outcomes through strategic collaboration.”

Earlier this year, Proveris began offering cGMP compliant contract OINDP characterization services, and the company has announced a number of new hires over the past year, including two recent appointments.

Read the Proveris Scientific press release.

Share

published on

May 10-May 14RDD 2026, Phoenix, AZ, USA

May 15-May 16: ATS Respiratory Innovation Summit 2026, Orlando, FL, USA

May 17-May 20: ATS International Conference 2026, Orlando, FL, USA

June 10SMI.London 2026, London, UK

July 13-July 162026 ISAM Congress, Taipei, Taiwan